Table 4 |
||||||
|
Treatment results of selected series of GBM and GBMO |
||||||
|
series |
patient group |
n |
treatment |
median overall survival (months) |
2-year overall survival |
reference |
|
|
||||||
|
NOA-01 |
all GBM |
154 |
post-OP RT + ACNU/VM26 |
17.3 |
25% |
[7] |
|
EORTC 26981 |
all GBM |
287 |
post-OP RT + TEM |
14.6 |
26.5% |
[5] |
|
RTOG 83-02 |
GBMO |
23 |
post-OP RT + BCNU |
14.3 |
(3-year survival: 35%) |
[4] |
|
retrospective |
GBMO |
12 |
resection + RT, chemo in 2/12 |
26 |
58% (data taken from graph) |
[8] |
|
retrospective |
GBMO |
11 |
post-OP RT in 65% (total group) |
17.7 |
20% (data taken from graph) |
[18] |
|
retrospective |
GBMO |
5 |
post-OP RT in 80% |
16.2 |
n. a. |
[19] |
|
present series |
GBMO |
10 |
post-OP RT + ACNU/VM26 (8/10) |
26 |
60% |
|
|
|
||||||
|
Overview of treatment results in glioblastoma multiforme (GBM) and GBM with oligodendroglial component (GBMO) from selected series (RT: radiotherapy, ACNU: nimustine, VM26: teniposide, TEM: temozolomide, n. a.: not available). |
||||||
|
Vordermark et al. BMC Cancer 2006 6:247 doi:10.1186/1471-2407-6-247 |
||||||
